---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-038686"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2024-03-26T23:59:59+00:00"
generated_at: "2026-06-04T07:47:42.474544+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics reports FY2023 net loss of $25.8M, cash runway through May 2025

## Summary
- Net loss of $25.8M ($0.86 per share) for FY2023 vs $21.4M ($0.91 per share) in FY2022.
- Cash and equivalents $29.9M at Dec 31, 2023; NIA grant funds of $67.5M remain available.
- March 2024 follow-on offering raised ~$10.4M net, extending cash runway through May 2025.
- Topline results from Phase 2 SHINE study (Alzheimer's) expected mid-2024; SHIMMER (DLB) in 2H2024.
- R&D expenses rose to $37.2M from $30.3M, mainly due to Phase 2 trial activities.

## SEC filing metadata
- accession: 0001104659-24-038686
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2024-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/0001104659-24-038686-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/tm249736d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-038686
- JSON: https://secwatch.observer/filing/0001104659-24-038686.json
- Plain text: https://secwatch.observer/filing/0001104659-24-038686.txt

## Key facts
- Earnings Releases
  COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.
  - Period: the year ended December 31, 2023
  - Net income: $25.8 million
  - EPS: $(0.86) per basic and diluted share
  - Result: reported results
  source text: The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1455365/000110465924038686/0001104659-24-038686-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.